JSM Heart Surgery Cases and Images

Drug Eluting Stent Restenosis

Review Article | Open Access Volume 2 | Issue 1 |

  • 1. Department of Cardiovascular Medicine, Beni Suef University, Egypt
+ Show More - Show Less
Corresponding Authors
Mostafa el mokadem, Department of Cardiovascular Medicine, Beni Suef University, Egypt Tel: 00201009414408;

n-stent restenosis has been a longstanding problem after percutaneous coronary intervention. Randomized trials comparing drug-eluting stents (DES) with bare-metal stents (BMS) have shown that the former significantly reduce the incidence of angiographic and clinical restenosis. The introduction of the drug-eluting stent (DES) successfully reduced the rate of restenosis; however, it is not completely diminished. Multiple factors may be involved in the mechanism of DES restenosis. Next to incomplete coverage with DES of the vessel segment injured by balloon angioplasty, factors such as stent under expansion, stent overexpansion, and non-uniform distribution of stent struts have been associated with DES restenosis. In addition, worse outcomes after repeat revascularization compared to BMS restenosis are reported in DES restenosis. Management of DES restenosis is an emerging issue, which requires careful evaluation of the restenosed lesion, together with determination of therapeutic strategy. There is no consensus at present on how to treat post-DES restenosis.


In-Stent Restenosis , Drug-Eluting Stent, Intravascular ultrasound, Zotralimus Eluting Stents, Acute coronary syndrome


el Mokadem M (2018) Drug Eluting Stent Restenosis. JSM Heart Surg Case Images 2(1): 1009.


Bare metal stent (BMS) restenosis is expected to occur within 6 months of intervention [1]. Drug-eluting stents (DES) proved to be superior to bare metal stents (BMS) in reducing restenosis rate and the need for repeat revascularization compared with bare metal stents [2-3].In spite of low rate of drug eluting stent restenosis, its management looks to be challenging. The clinical presentation of drug eluting stent restenosis is usually effort angina but some patients may present with acute coronary syndrome.


Angiographic in stent restenosis is defined as reduction of lumen diameter after percutaneous intervention (PCI), it looks to be of clinical significance if more than 50%. Use of Fractional flow reserve (FFR) and intravascular ultrasound (IVUS) can be helpful during evaluation of intermediate lesions [4-5].

Intravascular ultrasound (IVUS) provides detailed information about reference vessel diameter, minimal lumen diameter before and after stenting, percent lumen stenosis, distribution of intimal tissue and presence of stent under expansion with possible need for post stent dilatation with non-compliant balloon. Clinical restenosis is defined as presence of angiographic stenosis more than 50% plus one of the following: a) recurrent anginal pain related to restenotic lesion b) objective evidence of ischemia either during resting or exercise ECG c) abnormal results of functional diagnostic test e.g. FFR less than 0.8 [6]. The clinical effect of a DES is dependent on its components: stent platform, active pharmacologic compound, and drug carrier. The new generations of DES, such as everolimus eluting stents (EES), zotralimus eluting stents (ZES) and biolimus A9 eluting stents are characterized by improvements in stent platform (thin-strut cobalt chromium vs. thick-strut stainless steel), polymer (thinner and/or biodegradable or even polymer free in other DES), and drug (biolimus A9, zotralimus designed for coronary stents). Second generation DES proved to be superior to first generation DES especially paclitaxel eluting stent regarding the need for target lesion revascularization and stent thrombosis [7].


DES restenosis rates are related to degree of lesion complexity in addition to clinical risk factors. In simple lesions, restenosis rate is expected to be less than 5% at 1 year [8]. However, in more complex lesions, restenosis rate is expected to be 10% at 2 years [9]. The exact mechanism of drug eluting stent restenosis is to some extent controversial. Biological, mechanical, and technical factors may be involved.

Biological factors

Limus based drugs like sirolimus have cytostatic effect. They suppress smooth muscle cell migration and proliferation by arresting the cell cycle in the G1 phase [10]. Paclitaxel has a cytotoxic effect, binding specifically to the beta-tubulin subunit of microtubules; interfering with microtubule dynamics, preventing their depolymerization [10]. Genetic mutations affect the sensitivity to these drugs, leading to resistance to sirolimus, its analogs, or paclitaxel [11].


The predominant stent platform for BMS and first-generation DES is 316L stainless steel. Allergic reactions to nickel and molybdenum released from 316L stainless steel stents may be the mechanism for in stent restenosis [12]. The stent platform used in new generation DES like everolimus eluting stents (EES) is cobalt chromium, which has lower nickel content than 316L stainless steel, and does not appear to trigger proliferative response and hypersensitivity reaction as compared with BMS and older generations of DES. However hypersensitivity

Figure 1 Showing mal apposition with blood accumulation behind stent struts.

Figure 1: Showing mal apposition with blood accumulation behind stent struts.

reactions may occur in response to other components of DES like drug or and polymer. Use of polymer free DES seems to reduce hypersensitivity and inflammatory reactions incriminated in instent restenosis and thrombosis.

Stent under expansion: Stent under expansion results from suboptimal expansion during implantation rather than from stent recoil [13]. Stent under expansion usually occurs in setting of tight markedly calcified lesions, so adequate lesion preparation before stenting either by simple balloon pre dilatation or use of rotational atherectomy device in setting of marked calcifications seems to be crucial. Post stent dilatation with non compliant balloon can also correct any residual under expansion or malapposition.

The use of IVUS can be useful to detect under expansion despite good apposition of the stent struts to the vessel wall with smaller stent cross-sectional area compared with vessel crosssectional area in the same site and also with reference vessel area. Excellent expansion is evident when the minimum lumen area in the stent is ≥ 90% of the average reference lumen area [14].

A condition that needs to be differentiated from under expansion is stent malapposition; unlike under expansion, there are stent struts not opposed to the vessel wall (i.e. space occupied by blood can be detected between the stent struts and the arterial intima) (Figure 1).

Malapposition is considered an important predisposing factor for stent thrombosis and restenosis. It can be diagnosed by IVUS or OCT. In IVUS malapposition is defined as a separation of at least one stent strut from the intimal surface of the arterial wall that is not overlapping a side branch and has evidence of blood flow behind the strut [15]. In contrast to IVUS, Optical coherence tomography (OCT) has a resolution of 10-20 µm, which is about 10 times higher than that of IVUS (80-120 µm). Malapposition is defined by OCT as a distance between the strut marker and lumen contour greater than the strut thickness plus the axial resolution of OCT [16].

Stent fracture: A stent fracture is defined as complete or partial separation of a stent at follow-up that was contiguous after the original stent implantation [17]. The reported incidence of stent fracture ranges between 0.8 and 19% [18]. Stent fracture is usually associated with binary restenosis, thrombosis, aneurysm, embolization, ischemic events, and target lesion revascularization (TLR) and could thereby increase morbidity and mortality [19]. Several studies have reported a rise in in-stent restenosis (ISR) with stent fracture [20]. It has been suggested that stent fracture leads to impaired and unequal local drug delivery at the fractured site [21].

Stent fracture can be diagnosed by IVUS where partial stent fracture is characterized by the absence of at least one-third or 120° of stent struts for at least 1 frame while complete stent fracture is characterized by complete absence of stent struts within the stented segment for at least 1 frame [17]. Multi slice CT is another diagnostic modality for detection of stent fracture [22]. Excessive tortuosity, angulation and torsion of the vessel, overlapping stents, longer stents, and SES (owing to its rigid closed-cell structure) are associated with increased risk of stent fracture [23-25].

Technical factors

As known that balloon is slightly 1-2 mm longer than stent itself. This leads to presence of area of vessel wall exposed to injury effect of balloon inflation but not covered by the stent i.e. not exposed to drug antiestenotic effect. Subgroup analyses from an early SES randomized clinical trial showed instent estenosis may occur predominantly at the proximal stent margin after SES implantation [26].

This was decreased in subsequent studies that with recommended technique of pre-dilation with shorter balloons use of a single long stent enough to cover whole diseased segment.

Stent Gap is another predisposing factor for instent restenosis similar to stent fracture where drug delivery in the vessel wall is minimal at the gap site. So overlapping DES with avoidance of short stent gaps is extremely important where there is defective drug delivery, this should be followed by post stent dilatation at overlapping segment preferably by using non compliant balloon [27].


DES proved to be superior to BMS in reducing the risk of instent restenosis and need for target lesion revascularization.

DES restenosis is related to degree of lesion complexity in addition to clinical risk factors where in simple lesions restenosis rate is e less than 5% at 1 year. However, in more complex lesions, restenosis rate increased to be 10% at 2 years. The exact mechanism of drug eluting stent restenosis is to some extent controversial. Biological, mechanical, and technical factors may be involved. Understanding the mechanism of restenosis in every case is important as it will be guide for optimal modality of treatment. 


1. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996; 334: 561-566.

2. Finn A, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007; 27: 1500-1510.

3. Park D, Hong M, Mintz G, Lee CW, Song JM, Han KH, et al. Twoyear follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxeleluting stent implantation: late “catch-up” phenomenon from ASPECT Study. J Am Coll Cardiol. 2006; 48: 2432-2439.

4. Jasti V, Ivan E, Yalamanchili V, Wongpraparut N, Leesar M. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation. 2004; 110: 2831-2836.

5. Doi H, Maehara A, Mintz GS, Neil J. Weissman, Alan Yu, Hong Wang, et al. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials. Circ Cardiovasc Interv. 2008; 1: 111-118.

6. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115: 2344-2351.

7. Kedhi E, Joesoef KS, McFadden E, Wassing J, Van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomized trial. Lancet. 2010; 375: 201-209.

8. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus- Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009; 53: 1488-1497.

9. Byrne R, Iijima R, Mehilli J, Pache J, Schulz S, Schömig A, et al. Treatment of paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes. Rev Esp Cardiol. 2008; 61: 1134-1139.

10. Costa M, Simon D. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005; 111: 2257-2273.

11. Yusuf R, Duan Z, Lamendola D, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003; 3: 1-19

12. Huang S, Houghton P. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001; 4: 378 -391.

13. Mintz G. Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. Am J Cardiol. 2007; 100: 26M-35M.

14. De Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I, et al. Intravascular ultrasound guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries study (MUSIC study). Eur Heart J. 1998; 19: 1214-1223.

15. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006; 113: 414-419.

16. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012; 59: 1058-1072.

17. Doi H, Maehara A, Mintz G, Tsujita K, Kubo T, Castellanos C, et al. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol. 2009; 103: 818-823.

18. Ino Y, Toyoda Y, Tanaka A , Ishii S, Kusuyama Y, Kubo T, et al. Predictors and prognosis of stent fracture after sirolimus-eluting stent implantation. Circ J. 2009; 73: 2036-2041.

19. Canan T, Lee MS. Drug-eluting stent fracture: incidence. contributing factors, and clinical implications. Catheter Cardiovasc Interv. 2010; 75: 237-245.

20. Shaikh F, Maddikunta R, Djelmami-Hani M, Solis J, Allaqaband S, Bajwa T. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis? Catheter Cardiovasc Interv. 2008; 71: 614-618.

21. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007; 69: 380-386.

22. Hecht HS, Polena S, Jelnin V, et al. Stent gap by 64-detector computed tomographic angiography relationship to in-stent restenosis, Fracture, and overlap failure. J Am Coll Cardiol. 2009; 54: 1949-1959.

23. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007; 69: 380-386.

24. Lee M, Jurewitz D, Aragon J, Forrester J, Makkar RR, Kar S, et al. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. Catheter Cardiovasc Interv. 2007; 69: 387-394.

25. Umeda H, Gochi T, Iwase M, Izawa H, Shimizu T, Ishiki R, et al. Frequency, predictors and outcome of stent fracture after sirolimuseluting stent implantation. Int J Cardiol. 2009; 133: 321-326.

26. Moses J, Leon M, Popma J, Fitzgerald P, David R. Holmes, Charles O’Shaughnessy, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-1323.

27. Kereiakes D, Wang H, Popma J, Kuntz RE, Donohoe DJ, Schofer J, et al. Periprocedural and late consequences of overlapping cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006; 48: 21-31.

el Mokadem M (2018) Drug Eluting Stent Restenosis. JSM Heart Surg Case Images 2(1): 1009.

Received : 23 Oct 2017
Accepted : 22 Jan 2018
Published : 25 Jan 2018
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X